血浆 miR-30a-5p 作为一种早期新型的非侵入性肺癌诊断和预后生物标志物。
Plasma miR-30a-5p as an early novel noninvasive diagnostic and prognostic biomarker for lung cancer.
机构信息
Division of General Practice & Section for Pedagogic Research on General Practice, West China Hospital, Sichuan University, Chengdu 610041, PR China.
Department of Respiratory & Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, PR China.
出版信息
Future Oncol. 2019 Nov;15(32):3711-3721. doi: 10.2217/fon-2019-0393. Epub 2019 Oct 30.
Circulation miRNAs have become increasingly appreciated in the diagnosis and prognosis of lung cancer. This study aims to identify and evaluate plasma miRNA-30a-5p as an early noninvasive biomarker for the diagnosis and prognosis of lung cancer. Expression levels of plasma miRNA 30a-5p were measured by quantitative real-time PCR. Receiver operating characteristic analysis and area under the curve were used to differentiate malignant from benign tumors and from healthy controls. Kaplan-Meier curves and Cox regression were used to determine survival and prognosis. Our results suggest that the level of miRNA-30a-5p in plasma might be a considerable early novel noninvasive diagnostic and prognostic biomarker for lung cancer. Prospective studies must be performed to confirm this new early novel noninvasive diagnostic and prognostic biomarker for lung cancer.
循环 miRNA 在肺癌的诊断和预后中越来越受到重视。本研究旨在鉴定和评估血浆 miRNA-30a-5p 作为肺癌早期无创诊断生物标志物的价值。采用实时定量 PCR 法检测血浆 miRNA 30a-5p 的表达水平。通过绘制受试者工作特征曲线和计算曲线下面积，比较良、恶性肿瘤与健康对照组之间的差异。采用 Kaplan-Meier 曲线和 Cox 回归分析评估患者的生存和预后情况。我们的研究结果提示，血浆 miRNA-30a-5p 水平可能是一种有前途的肺癌早期新型无创诊断和预后生物标志物。还需要开展前瞻性研究来进一步证实血浆 miRNA-30a-5p 作为肺癌早期新型无创诊断和预后生物标志物的价值。
Zotero 插件